Long-Term Follow-Up of Checkpoint Inhibitor-Associated Uveitis Treated with Fluocinolone Acetonide Intravitreal Implant in a Pediatric Patient. (PubMed, Ocul Immunol Inflamm) - Sep 27, 2026 - "To describe the clinical course and 2-year follow-up of a pediatric patient treated with 0.18 mg fluocinolone acetonide intravitreal implants (Yutiq, EyePoint Pharmaceuticals) for chronic, bilateral immune checkpoint inhibitor (ICI)-associated uveitis...A 15-year-old female patient with advanced epithelioid peritoneal mesothelioma on pembrolizumab and ipilimumab therapy developed chronic, bilateral ICI-associated anterior and intermediate uveitis failing topical corticosteroids was treated with bilateral intravitreal 0.18 mg fluocinolone acetonide implants, avoiding systemic immunosuppression...The intravitreal fluocinolone acetonide 0.18 mg implant may be an effective treatment for recalcitrant ICI-associated intermediate uveitis in the pediatric population, providing long-term control of inflammation while preserving immunotherapy effectiveness. Careful follow-up is needed to monitor for complications of uveitis and corticosteroid treatment."
Checkpoint inhibition • Journal • Cardiovascular • Cataract • Epithelioid Peritoneal Mesothelioma • Glaucoma • Mesothelioma • Ocular Inflammation • Oncology • Ophthalmology • Pediatrics • Peritoneal Mesothelioma • Solid Tumor • Uveitis
|
|
Brian Turpin; Lauren Diroff; Lindsay Haacker; Robert A Sisk; Roselind L Ni; Veeral Shah; Virginia A Miraldi Utz
|